Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP

Next Previous
Trial Profile

A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 27 Dec 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Canakinumab (Primary)
  • Indications Cardiovascular disorders
  • Focus Proof of concept; Registrational; Therapeutic Use
  • Acronyms CANTOS; CANTOS sub-study 1; CANTOS sub-study 2
  • Sponsors Novartis; Novartis Pharmaceuticals

Most Recent Events

  • 13 Nov 2023 Results validating associations between SUA and CV risk in a large cohort with chronic CAD and determining whether these associations were altered by IL-1b blockade or baseline renal function, presented at the American Heart Association Scientific Sessions 2023
  • 15 Jun 2023 Results assessing Impact of Clonal Hematopoiesis and Canakinumab on Non-Hematological Malignancy presented at the 28th Congress of the European Haematology Association
  • 09 Aug 2022 Results published in the European Heart Journal

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top